Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours
Overexpression of HER-2/neu in human breast carcinomas correlates with poor prognosis, although its strength as a prognostic indicator varies widely in different reports. Variability may be due to active signalling by HER-2/neu in a subset of the tumours in which it is overexpressed. To study this h...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 1996-09, Vol.74 (5), p.802-806 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 806 |
|---|---|
| container_issue | 5 |
| container_start_page | 802 |
| container_title | British journal of cancer |
| container_volume | 74 |
| creator | DiGiovanna, MP Carter, D Flynn, SD Stern, DF |
| description | Overexpression of HER-2/neu in human breast carcinomas correlates with poor prognosis, although its strength as a prognostic indicator varies widely in different reports. Variability may be due to active signalling by HER-2/neu in a subset of the tumours in which it is overexpressed. To study this hypothesis, we have developed an activation state-specific anti-HER-2/neu monoclonal antibody. In this report, we use this antibody to analyse the signalling status of HER-2/neu in a large series of invasive breast carcinomas. Overexpression of HER-2/neu was detected in 9% of 223 cases. Of the cases demonstrating overexpression, active signalling by HER-2/neu was detected in only 35%. The clinicopathological characteristics of these cases are described. This functional assay is predicted to improve the utility of HER-2/ neu as a prognostic indicator. |
| doi_str_mv | 10.1038/bjc.1996.439 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2074709</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78320750</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-198bcd1d729ce8bb95737ea229a4257f78fdbb6222fc7699e8e69be9051191183</originalsourceid><addsrcrecordid>eNqFkUGLEzEUx4Moa129eRVyEE9ON8l0JslFWJZdV1gQRM8hybzppswkNW-m2A_g9zalpSoInkL4_97Le_kR8pqzJWe1unIbv-Rat8tVrZ-QBW9qUXEl5FOyYIzJimnBnpMXiJty1UzJC3KhpG4a1SzIz7s5-imkaAdqEe2e9inT-9svlbiKMNMOxhRxynYCpLaQO6AY1gUfQlzTEKmlY4gph2lPU_-7sko7yPBjmwHxSO4sHqof59FG6jJYnOg0j2nO-JI86-2A8Op0XpJvd7dfb-6rh88fP91cP1R-JeVUca2c73gnhfagnNONrCVYIbRdiUb2UvWdc60Qovey1RoUtNqBZg3nmnNVX5IPx77b2Y3QeYhls8Fscxht3ptkg_k7ieHRrNPOCCZXkunS4N2pQU7fZ8DJjAE9DIONkGY0UtUFbdh_Qd6otlZSFPD9EfQ5IWboz9NwZg5-TfFrDn5N8VvwN39ucIZPQkv-9pRb9Hbos40-4BmrBWdcHj6iOmJYkriGbDbFQ7GK_372F3LUv4U</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15863872</pqid></control><display><type>article</type><title>Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>DiGiovanna, MP ; Carter, D ; Flynn, SD ; Stern, DF</creator><creatorcontrib>DiGiovanna, MP ; Carter, D ; Flynn, SD ; Stern, DF</creatorcontrib><description>Overexpression of HER-2/neu in human breast carcinomas correlates with poor prognosis, although its strength as a prognostic indicator varies widely in different reports. Variability may be due to active signalling by HER-2/neu in a subset of the tumours in which it is overexpressed. To study this hypothesis, we have developed an activation state-specific anti-HER-2/neu monoclonal antibody. In this report, we use this antibody to analyse the signalling status of HER-2/neu in a large series of invasive breast carcinomas. Overexpression of HER-2/neu was detected in 9% of 223 cases. Of the cases demonstrating overexpression, active signalling by HER-2/neu was detected in only 35%. The clinicopathological characteristics of these cases are described. This functional assay is predicted to improve the utility of HER-2/ neu as a prognostic indicator.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1996.439</identifier><identifier>PMID: 8795585</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Antibodies, Monoclonal - analysis ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Breast Neoplasms - genetics ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Breast Neoplasms - surgery ; Cancer Research ; Carcinoma in Situ - genetics ; Carcinoma in Situ - metabolism ; Carcinoma in Situ - pathology ; Carcinoma in Situ - surgery ; Carcinoma, Ductal, Breast - genetics ; Carcinoma, Ductal, Breast - metabolism ; Carcinoma, Ductal, Breast - pathology ; Carcinoma, Ductal, Breast - surgery ; Drug Resistance ; Epidemiology ; experimental-oncology ; Female ; Gene Expression Regulation, Neoplastic ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry - methods ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Molecular Medicine ; Oncology ; Prognosis ; Receptor, ErbB-2 - biosynthesis ; Receptor, ErbB-2 - genetics ; Receptors, Estrogen - analysis ; Retrospective Studies ; Signal Transduction - physiology ; Staining and Labeling ; Tumors</subject><ispartof>British journal of cancer, 1996-09, Vol.74 (5), p.802-806</ispartof><rights>Cancer Research Campaign 1996</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-198bcd1d729ce8bb95737ea229a4257f78fdbb6222fc7699e8e69be9051191183</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074709/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074709/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,41488,42557,51319,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3210178$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8795585$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DiGiovanna, MP</creatorcontrib><creatorcontrib>Carter, D</creatorcontrib><creatorcontrib>Flynn, SD</creatorcontrib><creatorcontrib>Stern, DF</creatorcontrib><title>Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Overexpression of HER-2/neu in human breast carcinomas correlates with poor prognosis, although its strength as a prognostic indicator varies widely in different reports. Variability may be due to active signalling by HER-2/neu in a subset of the tumours in which it is overexpressed. To study this hypothesis, we have developed an activation state-specific anti-HER-2/neu monoclonal antibody. In this report, we use this antibody to analyse the signalling status of HER-2/neu in a large series of invasive breast carcinomas. Overexpression of HER-2/neu was detected in 9% of 223 cases. Of the cases demonstrating overexpression, active signalling by HER-2/neu was detected in only 35%. The clinicopathological characteristics of these cases are described. This functional assay is predicted to improve the utility of HER-2/ neu as a prognostic indicator.</description><subject>Antibodies, Monoclonal - analysis</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - surgery</subject><subject>Cancer Research</subject><subject>Carcinoma in Situ - genetics</subject><subject>Carcinoma in Situ - metabolism</subject><subject>Carcinoma in Situ - pathology</subject><subject>Carcinoma in Situ - surgery</subject><subject>Carcinoma, Ductal, Breast - genetics</subject><subject>Carcinoma, Ductal, Breast - metabolism</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Carcinoma, Ductal, Breast - surgery</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>experimental-oncology</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunohistochemistry - methods</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - biosynthesis</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptors, Estrogen - analysis</subject><subject>Retrospective Studies</subject><subject>Signal Transduction - physiology</subject><subject>Staining and Labeling</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUGLEzEUx4Moa129eRVyEE9ON8l0JslFWJZdV1gQRM8hybzppswkNW-m2A_g9zalpSoInkL4_97Le_kR8pqzJWe1unIbv-Rat8tVrZ-QBW9qUXEl5FOyYIzJimnBnpMXiJty1UzJC3KhpG4a1SzIz7s5-imkaAdqEe2e9inT-9svlbiKMNMOxhRxynYCpLaQO6AY1gUfQlzTEKmlY4gph2lPU_-7sko7yPBjmwHxSO4sHqof59FG6jJYnOg0j2nO-JI86-2A8Op0XpJvd7dfb-6rh88fP91cP1R-JeVUca2c73gnhfagnNONrCVYIbRdiUb2UvWdc60Qovey1RoUtNqBZg3nmnNVX5IPx77b2Y3QeYhls8Fscxht3ptkg_k7ieHRrNPOCCZXkunS4N2pQU7fZ8DJjAE9DIONkGY0UtUFbdh_Qd6otlZSFPD9EfQ5IWboz9NwZg5-TfFrDn5N8VvwN39ucIZPQkv-9pRb9Hbos40-4BmrBWdcHj6iOmJYkriGbDbFQ7GK_372F3LUv4U</recordid><startdate>19960901</startdate><enddate>19960901</enddate><creator>DiGiovanna, MP</creator><creator>Carter, D</creator><creator>Flynn, SD</creator><creator>Stern, DF</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19960901</creationdate><title>Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours</title><author>DiGiovanna, MP ; Carter, D ; Flynn, SD ; Stern, DF</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-198bcd1d729ce8bb95737ea229a4257f78fdbb6222fc7699e8e69be9051191183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Antibodies, Monoclonal - analysis</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - surgery</topic><topic>Cancer Research</topic><topic>Carcinoma in Situ - genetics</topic><topic>Carcinoma in Situ - metabolism</topic><topic>Carcinoma in Situ - pathology</topic><topic>Carcinoma in Situ - surgery</topic><topic>Carcinoma, Ductal, Breast - genetics</topic><topic>Carcinoma, Ductal, Breast - metabolism</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Carcinoma, Ductal, Breast - surgery</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>experimental-oncology</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunohistochemistry - methods</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - biosynthesis</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptors, Estrogen - analysis</topic><topic>Retrospective Studies</topic><topic>Signal Transduction - physiology</topic><topic>Staining and Labeling</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DiGiovanna, MP</creatorcontrib><creatorcontrib>Carter, D</creatorcontrib><creatorcontrib>Flynn, SD</creatorcontrib><creatorcontrib>Stern, DF</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DiGiovanna, MP</au><au>Carter, D</au><au>Flynn, SD</au><au>Stern, DF</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1996-09-01</date><risdate>1996</risdate><volume>74</volume><issue>5</issue><spage>802</spage><epage>806</epage><pages>802-806</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Overexpression of HER-2/neu in human breast carcinomas correlates with poor prognosis, although its strength as a prognostic indicator varies widely in different reports. Variability may be due to active signalling by HER-2/neu in a subset of the tumours in which it is overexpressed. To study this hypothesis, we have developed an activation state-specific anti-HER-2/neu monoclonal antibody. In this report, we use this antibody to analyse the signalling status of HER-2/neu in a large series of invasive breast carcinomas. Overexpression of HER-2/neu was detected in 9% of 223 cases. Of the cases demonstrating overexpression, active signalling by HER-2/neu was detected in only 35%. The clinicopathological characteristics of these cases are described. This functional assay is predicted to improve the utility of HER-2/ neu as a prognostic indicator.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>8795585</pmid><doi>10.1038/bjc.1996.439</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 1996-09, Vol.74 (5), p.802-806 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2074709 |
| source | MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Antibodies, Monoclonal - analysis Biological and medical sciences Biomedical and Life Sciences Biomedicine Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology Breast Neoplasms - surgery Cancer Research Carcinoma in Situ - genetics Carcinoma in Situ - metabolism Carcinoma in Situ - pathology Carcinoma in Situ - surgery Carcinoma, Ductal, Breast - genetics Carcinoma, Ductal, Breast - metabolism Carcinoma, Ductal, Breast - pathology Carcinoma, Ductal, Breast - surgery Drug Resistance Epidemiology experimental-oncology Female Gene Expression Regulation, Neoplastic Gynecology. Andrology. Obstetrics Humans Immunohistochemistry - methods Mammary gland diseases Medical sciences Middle Aged Molecular Medicine Oncology Prognosis Receptor, ErbB-2 - biosynthesis Receptor, ErbB-2 - genetics Receptors, Estrogen - analysis Retrospective Studies Signal Transduction - physiology Staining and Labeling Tumors |
| title | Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T05%3A33%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Functional%20assay%20for%20HER-2/neu%20demonstrates%20active%20signalling%20in%20a%20minority%20of%20HER-2/neu-overexpressing%20invasive%20human%20breast%20tumours&rft.jtitle=British%20journal%20of%20cancer&rft.au=DiGiovanna,%20MP&rft.date=1996-09-01&rft.volume=74&rft.issue=5&rft.spage=802&rft.epage=806&rft.pages=802-806&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1996.439&rft_dat=%3Cproquest_pubme%3E78320750%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15863872&rft_id=info:pmid/8795585&rfr_iscdi=true |